دورية أكاديمية

Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.

التفاصيل البيبلوغرافية
العنوان: Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
المؤلفون: Morgans, Alicia K., Shore, Neal D., Khan, Nasreen, Constantinovici, Niculae, Khan, Javeed, Chen, Guifang, Xu, Julie, Ortiz, Jorge A., George, Daniel J.
المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p5097-5097, 1p
قاعدة البيانات: Supplemental Index
الوصف
تدمد:0732183X
DOI:10.1200/JCO.2023.41.16_suppl.5097